Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.
The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.